Pathogenesis-based application of biologics for chronic rhinosinusitis: Current and future perspectives

• Published in: Auris, nasus, larynx nasus, larynx, 2024-04, Vol.51 (2), p.371-378
• Main Authors: Okano, Mitsuhiro, Kanai, Kengo, Oka, Aiko
• Format: Article
• Language: English
• Subjects: Biologics; Chronic rhinosinusitis; Endotype; Inflammation; Nasal polyps
• ISSN: 0385-8146; 1879-1476
• DOI: 10.1016/j.anl.2023.08.005

Chronic rhinosinusitis (CRS) is heterogeneous and contains diverse pathogenesis including type 1, type 2, and/or type 3 inflammation. For severe type 2 CRS especially CRS with nasal polyps (CRSwNP), biologics that target inflammatory molecules have recently been applied along with further changes in the treatment algorithm for CRS. Currently, a completed phase 3 clinical trial for biologics for severe CRSwNP with inadequate response to surgery and/or intranasal corticosteroids, including omalizumab (anti-IgE), mepolizumab (anti-IL-5), benralizumab (anti-IL-5Rα), and dupilumab (anti-IL-4Rα), have all shown efficacy. Similar phase 3 clinical trials for tezepelumab (anti-TSLP) and etokimab (anti-IL-33) are now underway and completed, respectively. Further studies need to evaluate how to optimally and cost-effectively use biologics for CRS and determine if any biomarkers are indicative of which biologics should be administered. A definition of complete and/or clinical remission of CRS is also needed to determine when to reduce or discontinue biologics. In addition, more precise basic research on CRS, such as endotyping and genotyping, will need to be undertaken in order to determine novel targets for biologics.